<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83364">
  <stage>Registered</stage>
  <submitdate>14/11/2008</submitdate>
  <approvaldate>8/01/2009</approvaldate>
  <actrnumber>ACTRN12609000014257</actrnumber>
  <trial_identification>
    <studytitle>Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir).</studytitle>
    <scientifictitle>Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).</scientifictitle>
    <utrn />
    <trialacronym>SKiT</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Human Immunodeficiency Virus (HIV)</healthcondition>
    <healthcondition>Cardiovascular function</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>using applanation tonometry to evaluate cardiovascular function  in adults with HIV infection switching from ABC-3TC (Kivexa) to TDF-FTC (Truvada) or from ABC (abacavir) to TDF (tenofovir).
Kivexa is a combination HIV pill of Abacavir and lamivudine and Abacavir alone is one of the two drugs in Kivexa. Truvada, another combination pill that contains the drugs tenofovir and emtricitabine and Tenofovir alone is one of the two drugs in Truvada. Truvada and Tenofovir are the two drugs to be used in this study. This is a 24 week study
Truvada dose is 1 x 300mg/200mg tablet, once daily, oral for 24 weeks.
Tenofovir dose is 1 x 300mg tablet, once daily oral for 24 weeks.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate cardiovascular function measured by radial artery applanation tonometry in HIV-infected adults switching from ABC-3TC to TDF-FTC (or from ABC to TDF).</outcome>
      <timepoint>Baseline and at twenty four weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To relate these functional arterial changes to HIV-related, metabolic and pro-inflammatory parameters. This will be done by looking at Tonometry reports done at various timepoints throughout the study as well as pathology blood results</outcome>
      <timepoint>twenty four weeks after the start of the study.
The outcome will be assessed also at weeks 4 and 12.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>provision of written, informed consent.
HIV-infected adults at least 18 years of age.
receiving stable antiretroviral therapy including ABC or ABC-3TC for at least six months.
HIV Ribonucleic Acid (RNA) &lt; 50 copies/ml for at least the previous 3 months.
Framingham risk score = 10%, OR diabetes, OR prior ischaemic cardiovascular disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>200</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>clinically significant renal or hepatic disease.
initiation of anti hypertensive therapy in the previous 30 days. 
initiation of therapy for dyslipidaemia in the previous 6 weeks. 
using corticosteroids, anti-inflammatory drugs or immunomodulating drugs.
contra-indications to TDF or TDF-FTC therapy (e.g. grade 3 renal dysfunction).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>23/09/2008</anticipatedstartdate>
    <actualstartdate>23/09/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/05/2009</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincents Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria St, Darlinghurst, NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincents Hospital</fundingname>
      <fundingaddress>390 Victoria St, Darlinghurst, NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose is to perform tonometry in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir). 
Hypothesis: that markers of cardiovascular function (as measured by applanation tonometry) will improve in patients switching from ABC-3TC to TDF-FTC.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Andrew Carr</name>
      <address>St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010</address>
      <phone>+61 2 8382 3359</phone>
      <fax />
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Registered Nurse (RN) Kate Sinn</name>
      <address>St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010</address>
      <phone>+61 2 8382 3060</phone>
      <fax />
      <email>ksinn@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>RN Robyn Richardson</name>
      <address>St Vincents Hospital
Level 4 Xavier Bldg
390 Victoria St, Darlinghurst, NSW 2010</address>
      <phone>+61 2 8382 3872</phone>
      <fax />
      <email>rrichardson1@stvincents.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Carr</name>
      <address>St Vincents Hospital
Xavier, Level 4, 390 Victortoria St
Darlinghurst, NSW, 2010
</address>
      <phone>+61 2 83823359</phone>
      <fax />
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>